NAROPIN
What it isLong-acting amide local anesthetic that blocks voltage-gated sodium channels; used for epidural, peripheral nerve, and local infiltration anesthesia.
Why this oneProvides prolonged sensory block with less motor block and less cardiotoxicity than comparable bupivacaine concentrations.
What limits itIntravascular injection or excessive dose causes local-anesthetic systemic toxicity; inject incrementally with aspiration and cardiorespiratory monitoring.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Surgical anesthesia (epidural, major nerve block, field block) | Adults | 0.5–1% (5–10 mg/mL) per block | — | Per block; e.g. epidural up to ~200 mg |
| Labor analgesia / acute postoperative pain (epidural infusion) | Adults | 0.2% (2 mg/mL) | — | Continuous epidural up to 28 mg/hr |
Renal Undefined
Hepatic Undefined
Dose varies by block type, site, and patient status; consult the block-specific dosage table.
Pregnancy No human data; crosses the placenta and can cause fetal/neonatal toxicity when used in labor.
Lactation Present in human milk at low levels; no adverse reactions reported in breastfed infants.
NO BOXED WARNINGS
Principal risklocal-anesthetic systemic toxicity from inadvertent intravascular injection
